319 related articles for article (PubMed ID: 24558065)
1. Predictive factors and patterns of recurrence in patients with triple negative breast cancer.
Steward L; Conant L; Gao F; Margenthaler JA
Ann Surg Oncol; 2014 Jul; 21(7):2165-71. PubMed ID: 24558065
[TBL] [Abstract][Full Text] [Related]
2. [Treatment outcomes and clinicopathologic characteristics of advanced triple-negative breast cancer patients].
Zhang P; Xu BH; Ma F; Li Q; Yuan P; Wang JY; Zhang P
Zhonghua Zhong Liu Za Zhi; 2011 May; 33(5):381-4. PubMed ID: 21875471
[TBL] [Abstract][Full Text] [Related]
3. Breast-conserving therapy for triple-negative breast cancer.
Gangi A; Chung A; Mirocha J; Liou DZ; Leong T; Giuliano AE
JAMA Surg; 2014 Mar; 149(3):252-8. PubMed ID: 24382582
[TBL] [Abstract][Full Text] [Related]
4. Eight Year Survival Analysis of Patients with Triple Negative Breast Cancer in India.
Chandra D; Suresh P; Sinha R; Azam S; Batra U; Talwar V; Kumar K; Mehta A
Asian Pac J Cancer Prev; 2016; 17(6):2995-9. PubMed ID: 27356724
[TBL] [Abstract][Full Text] [Related]
5. A comparison between young and old patients with triple-negative breast cancer: biology, survival and metastatic patterns.
Tzikas AK; Nemes S; Linderholm BK
Breast Cancer Res Treat; 2020 Aug; 182(3):643-654. PubMed ID: 32524352
[TBL] [Abstract][Full Text] [Related]
6. Prognostic value of breast cancer subtypes on breast cancer specific survival, distant metastases and local relapse rates in conservatively managed early stage breast cancer: a retrospective clinical study.
Sanpaolo P; Barbieri V; Genovesi D
Eur J Surg Oncol; 2011 Oct; 37(10):876-82. PubMed ID: 21824742
[TBL] [Abstract][Full Text] [Related]
7. Outcomes of triple-negative versus non-triple-negative breast cancers managed with breast-conserving therapy.
Bhatti AB; Khan AI; Siddiqui N; Muzaffar N; Syed AA; Shah MA; Jamshed A
Asian Pac J Cancer Prev; 2014; 15(6):2577-81. PubMed ID: 24761867
[TBL] [Abstract][Full Text] [Related]
8. Duration of anti-HER2 blockage therapy may improve survival in HER2 positive metastatic breast carcinoma patients.
Arslan UY; Turker I; Aksoy S; Oksuzoglu B; Helvaci K; Yildirim Ozdemir N; Uyeturk U; Uysal Sonmez O; Budakoglu B; Zengin N
J BUON; 2013; 18(3):585-93. PubMed ID: 24065468
[TBL] [Abstract][Full Text] [Related]
9. Human epidermal growth factor receptor-2 positivity predicts locoregional recurrence in patients with T1-T2 breast cancer.
Cefaro GA; Genovesi D; Trignani M; DI Nicola M
Anticancer Res; 2014 Mar; 34(3):1207-12. PubMed ID: 24596361
[TBL] [Abstract][Full Text] [Related]
10. Triple-negative breast cancer: the impact of guideline-adherent adjuvant treatment on survival--a retrospective multi-centre cohort study.
Schwentner L; Wolters R; Koretz K; Wischnewsky MB; Kreienberg R; Rottscholl R; Wöckel A
Breast Cancer Res Treat; 2012 Apr; 132(3):1073-80. PubMed ID: 22205141
[TBL] [Abstract][Full Text] [Related]
11. Prospective comparison of outcome after treatment for triple-negative and non-triple-negative breast cancer.
Joyce DP; Murphy D; Lowery AJ; Curran C; Barry K; Malone C; McLaughlin R; Kerin MJ
Surgeon; 2017 Oct; 15(5):272-277. PubMed ID: 28277293
[TBL] [Abstract][Full Text] [Related]
12. Unique characteristics and failure patterns of metaplastic breast cancer in contrast to invasive ductal carcinoma: a retrospective multicenter case-control study (KROG 13-07).
Yu JI; Choi DH; Huh SJ; Ahn SJ; Lee JS; Shin KH; Kwon Y; Kim YB; Suh CO; Kim JH; Cho J; Kim IA; Lee JH; Park W
Clin Breast Cancer; 2015 Apr; 15(2):e105-15. PubMed ID: 25459069
[TBL] [Abstract][Full Text] [Related]
13. [Prognostic value of estrogen receptor, progesterone receptor and human epidermal growth factor receptor-2 in node positive breast cancer patients treated by mastectomy].
Wang SL; Li YX; Song YW; Wang WH; Jin J; Liu YP; Liu XF; Yu ZH
Zhonghua Zhong Liu Za Zhi; 2010 Jul; 32(7):520-5. PubMed ID: 21029696
[TBL] [Abstract][Full Text] [Related]
14. Locoregional recurrence of breast cancer: a retrospective comparison of treatment methods.
Skowronek J; Piotrowski T
Neoplasma; 2002; 49(6):426-31. PubMed ID: 12584593
[TBL] [Abstract][Full Text] [Related]
15. Does immediate breast reconstruction after mastectomy and neoadjuvant chemotherapy influence the outcome of patients with non-endocrine responsive breast cancer?
Aurilio G; Bagnardi V; Graffeo R; Nolè F; Petit JY; Locatelli M; Martella S; Iera M; Rey P; Curigliano G; Rotmensz N; Munzone E; Goldhirsch A
Anticancer Res; 2014 Nov; 34(11):6677-83. PubMed ID: 25368274
[TBL] [Abstract][Full Text] [Related]
16. Similar outcomes between adenoid cystic carcinoma of the breast and invasive ductal carcinoma: a population-based study from the SEER 18 database.
Chen QX; Li JJ; Wang XX; Lin PY; Zhang J; Song CG; Shao ZM
Oncotarget; 2017 Jan; 8(4):6206-6215. PubMed ID: 28008158
[TBL] [Abstract][Full Text] [Related]
17. Prognostic factors for death after an isolated local recurrence in patients with early-stage breast carcinoma.
Lê MG; Arriagada R; Spielmann M; Guinebretière JM; Rochard F
Cancer; 2002 Jun; 94(11):2813-20. PubMed ID: 12115367
[TBL] [Abstract][Full Text] [Related]
18. Tumor characteristics and recurrence patterns in triple negative breast cancer: a comparison between younger (<65) and elderly (≥65) patients.
Königsberg R; Pfeiler G; Klement T; Hammerschmid N; Brunner A; Zeillinger R; Singer C; Dittrich C
Eur J Cancer; 2012 Nov; 48(16):2962-8. PubMed ID: 22647688
[TBL] [Abstract][Full Text] [Related]
19. Comparison of invasive micropapillary and triple negative invasive ductal carcinoma of the breast.
Chen HL; Ding A
Breast; 2015 Dec; 24(6):723-31. PubMed ID: 26392199
[TBL] [Abstract][Full Text] [Related]
20. Identification of patients with node-negative, triple-negative breast cancer who benefit from adjuvant cyclophosphamide, methotrexate, and 5-fluorouracil chemotherapy.
Wu CE; Chen SC; Lin YC; Lo YF; Hsueh S; Chang HK
Anticancer Res; 2014 Mar; 34(3):1301-6. PubMed ID: 24596377
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
